Holdings of EcoR1 Capital, LLC
24 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 91.8 % of the equity sleeve
Sector breakdown
- Unattributed 100.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- US 97.2 %
- BE 2.6 %
- GB 0.2 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | US | 22 | 1.9B $ | 97.20 % |
| 2 | BE | 1 | 50M $ | 2.58 % |
| 3 | GB | 1 | 4.4M $ | 0.23 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Zymeworks Inc | 22,970,388 | 575.2M $ | |
| 2 | AnaptysBio Inc | 7,880,094 | 437M $ | |
| 3 | CENTESSA PHARMACEUTICALS PLC | 6,000,000 | 238.3M $ | |
| 4 | Crinetics Pharmaceuticals Inc | 4,288,120 | 155.7M $ | |
| 5 | Aktis Oncology Inc | 4,824,469 | 86.3M $ | |
| 6 | ORIC Pharmaceuticals Inc | 6,728,116 | 85.2M $ | |
| 7 | CG oncology Inc | 1,102,000 | 74.6M $ | |
| 8 | Eton Pharmaceuticals Inc | 2,171,938 | 53.6M $ | |
| 9 | Galapagos NV | 1,667,119 | 50M $ | |
| 10 | Xencor Inc | 2,183,000 | 26.3M $ | |
| 11 | Neurogene Inc | 1,271,342 | 25.6M $ | |
| 12 | BridgeBio Oncology Therapeutics Inc | 2,823,126 | 25.3M $ | |
| 13 | MBX Biosciences Inc | 777,000 | 23.2M $ | |
| 14 | Relay Therapeutics Inc | 1,904,762 | 19M $ | |
| 15 | ZENAS BIOPHARMA INC | 789,500 | 15.4M $ | |
| 16 | Erasca Inc | 900,000 | 14.6M $ | |
| 17 | Eikon Therapeutics Inc | 732,606 | 7.8M $ | |
| 18 | Replimune Group Inc | 1,000,000 | 7.7M $ | |
| 19 | Phathom Pharmaceuticals Inc | 625,000 | 6.9M $ | |
| 20 | MEREO BIOPHARMA GROUP PLC | 13,368,855 | 4.4M $ | |
| 21 | Stoke Therapeutics Inc | 100,000 | 3.3M $ | |
| 22 | Prelude Therapeutics Inc | 947,049 | 3.2M $ | |
| 23 | IBIO INC | 1,583,000 | 3M $ | |
| 24 | Atara Biotherapeutics Inc | 99,593 | 471.1K $ |